Paul Mahon, an officer at United Therapeutics Corporation, has sold 8,300 shares of the company's common stock for approximately $4.97 million. This transaction, filed on November 5, 2026, is part of a series of stock sales that Mahon has conducted in recent months, reflecting a significant trading activity among executives in the pharmaceutical industry.

Background

United Therapeutics Corporation operates in the pharmaceutical preparations sector, specifically focusing on developing and commercializing innovative products to address the unmet needs of patients with chronic and life-threatening conditions. The company is incorporated in Delaware and is publicly traded on the NASDAQ under the ticker symbol UTHR. Recent filings include Form 144 on November 5, 2026, and Form 4 on October 16, 2026.

What the Filing Says

The SEC filing indicates that Mahon sold the shares on November 5, 2026, following a stock option exercise. The filing states, "The aggregate market value of the shares sold is $4,968,932.78," confirming the substantial value involved in this transaction.

Impact

This sale may affect investor perceptions of United Therapeutics, particularly regarding executive confidence in the company's future. The pharmaceutical industry, characterized by its competitive nature, often sees executives managing their stock holdings actively, which can influence market sentiment and investor decisions.

What's Next

The filing does not say what happens next.